🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise globally, with data suggesting in excess of 82 million infections each year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the context of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is employed against UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The research included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Clinicians on the front lines have shared hope. Having a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is deemed crucial to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea around the world.